Table 2 Summary of demographics, glucocorticoid dose, and treatments to reduce bone lossa for patients with or without morphometric vertebral fractures
Parameter | Vertebral fractures | ||
|---|---|---|---|
Overall | Present | Absent | |
N = 576 | N = 109 | N = 467 | |
Age, years | |||
Mean (SD) | 59.6 (15.00) | 69.7 (10.81) | 57.3 (14.88) |
P-valueb | <0.001 | ||
BMI, kg/m2 | |||
Mean (SD) | 26.8 (4.83) | 26.6 (3.61) | 26.9 (5.08) |
P-valueb | 0.724 | ||
Race, n (%) | |||
Caucasian | 566 (98.3) | 109 (100) | 457 (97.9) |
Black | 3 (0.5) | 0 (0.0) | 3 (0.6) |
American Indian or Alaska native | 5 (0.9) | 0 (0.0) | 5 (1.1) |
Other | 2 (0.3) | 0 (0.0) | 2 (0.4) |
Menopause, n (%) | |||
Started | 422 (73.3) | 104 (95.4) | 318 (68.1) |
Started at age ≤40 | 37 (6.4) | 11 (10.1) | 26 (5.6) |
Not started | 150 (26.0) | 4 (3.7) | 146 (31.3) |
Unknown | 4 (0.7) | 1 (0.9) | 3 (0.6) |
Time since menopause, years | |||
Mean (SD) | 18.1 (10.66) | 22.4 (10.06) | 16.7 (10.47) |
P-valueb | <0.001 | ||
Height, cm | |||
Mean (SD) | 158.2 (7.20) | 155.9 (7.61) | 158.7 (7.00) |
P-valueb | <0.001 | ||
Cumulative GC dose, g | |||
Mean (SD) | 15.5 (18.77) | 18.3 (23.00) | 14.9 (17.63) |
P-valueb | 0.346 | ||
Time from the start of GC use, years | |||
Mean (SD) | 7.4 (6.15) | 8.4 (7.60) | 7.1 (5.74) |
P-valueb | 0.279 | ||
Percentage of patients taking calcium and/or vitamin D | 49.3 | 52.3 | 48.6 |
Calcium | 45.0 | 49.5 | 43.9 |
Vitamin D | 45.0 | 51.4 | 43.5 |
Percentage of patients taking bisphosphonates | 42.7 | 66.1 | 37.3 |
Alendronate | 20.3 | 32.1 | 17.6 |
Risedronate | 16.5 | 22.9 | 15.0 |
Ibandronate | 9.7 | 19.3 | 7.5 |
Zoledronic acid | 1.2 | 2.8 | 0.9 |
Percentage of patients taking other medications | |||
Strontium ranelate | 2.3 | 3.7 | 1.9 |
Teriparatide | 1.9 | 6.4 | 0.9 |
Raloxifine | 1.2 | 2.8 | 0.9 |